Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Board OKs $200M Share Repurchase Program

NEW YORK (GenomeWeb) – Myriad Genetics announced after the close of the market Tuesday that its board of directors has approved an additional $200 million authorization for the firm's share repurchase program.

The company's previous share repurchase program began in 2010, and since then Myriad has repurchased nearly $1 billion of its stock. The repurchases are made via the open market or through privately negotiated purchases.

"Since the inception of the program we have repurchased over 38 million shares of our stock and we will continue to opportunistically repurchase shares at valuation thresholds that we believe do not reflect the long-term value of the Company and its product pipeline," Myriad Genetics CFO Bryan Riggsbee said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.